VETmAb BIO is a veterinary biopharmaceutical company focused on developing monoclonal antibodies ("mAbs") to treat debilitating diseases in dogs and cats. While monoclonal antibodies have provided revolutionary treatments in humans, mAbs technology has been underdeveloped in veterinary medicine. At VETmAb BIO, we’re taking advantage of human-validated targets and designing them specifically for dogs and cats, thereby mitigating technical risk. By utilizing our proprietary technologies, we can explore potential treatments to address various unmet needs in veterinary medicine.